Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vartumab C9scFv
- Development stage
- Unknown
- Lead developer
- Var2 Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vartumab C9scFv is a radiolabeled single-chain variable fragment (scFv) antibody fragment developed by VAR2 Pharmaceuticals for the molecular imaging of solid tumors. The agent consists of a proprietary scFv labeled with the positron-emitting isotope zirconium-89 (⁸⁹Zr), which specifically targets oncofetal Chondroitin Sulfate (ofCS). ofCS is a tumor-specific glycosaminoglycan that is expressed during fetal development and reappears in a wide variety of cancers, while remaining largely absent from healthy adult tissues. Vartumab C9scFv is currently being evaluated in the VARTUTRACE Phase 0 basket trial to assess its safety, biodistribution, and tumor-targeting efficiency in patients with various malignancies, including colorectal, pancreatic, and lung carcinomas, as well as glioblastoma and sarcomas.
- Other names
- Vartumab C9scFvC9scFvC-9scFvC 9scFv89Zr-Vartumab C9scFv89Zr-C9scFv
02
Targets
ofCS (Oncofetal chondroitin sulfate)
Beyond the preview
Go deeper on Vartumab C9scFv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vartumab C9scFv.